Current options in antifungal pharmacotherapy.
Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immunocompetent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug-interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections.
Mohr
John
J
Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center, Houston, Texas, USA. john.mohr@cubist.com
Johnson
Melissa
M
Cooper
Travis
T
Lewis
James S
JS
Ostrosky-Zeichner
Luis
L
D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D011090:Polyenes / Q000627:therapeutic use
D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D011090:Polyenes